血清sIL-2R、sCP检测对肿瘤患者化疗临床监测的应用价值

Clinical significance of serum sIL-2R and sCP level after chemotherapy in patients with tumor

【目的】探讨血清sIL-2R、sCP水平对肿瘤患者化疗前后的应用价值。【方法】应用酶联免疫吸附法(ELISA)和比色法测定45例肿瘤患者化疗前后血清sIL-2R、sCP浓度。【结果】所有肿瘤患者化疗前血清sIL-2R、sCP活力水平明显高于正常对照组,具有显著性差异(P<0.001)。化疗6个月后复发患者血清sIL-2R、sCP水平持续高于正常对照组,差异有统计学意义(P<0.05);未复发患者血清sIL-2R、sCP活力水平略高于正常对照组,但两组间比较差异无统计学意义(P>0.05)。【结论】血清sIL-2R、sCP表达水平对评价肿瘤患者化疗前后的病情和预后有一定临床意义。

[ Objective] To evaluate the clinical significance of serum concentrations of sIL- 2R, sCP in patients after chemotherapy with tumor for clinical monitoring. [Methods] The serum level of sIL-2R and sCP were measured by enzyme-linked immunosorbent assay （ELISA） and biochemical method in 45 patients with tumor beth before and after chemotherapy as well as in 40 healthy controls. [Results] The level of sIL-2R and sCP were significantly higher in the serum of tumor patients before chemotherapy than in the normal control group （ P 〈 0.1301） . Six months after chemotherapy the levels of patients without recurrence returned to normal. But in patients with recurrence the levels were about the same as those before chemotherapy. [ Conclusions] Serum concentrations of sIL-2R and sCP may reflect the progress of the disease and may be a potentially valuable parameter for predicting the prognosis and the patient＇s condition.